| Name | Losartan |
| Description | Losartan (DuP-753) is an angiotensin II receptor antagonist. |
| Cell Research | An MTT assay is used to measure cell proliferation and viability. For the assay, 5000 cells in 200?μL media per well are seeded in a 96 well plate. After overnight incubation to allow for cell attachment, the medium is removed by suction. MTT at 1?mg/mL concentration in serum-free medium is added and then incubated for 4?h at 37°C. After removal of MTT solution, 100?μL of DMSO is added to dissolve formazan crystals. Absorbance at 570?nm and at 600?nm as a reference is then measured using a microplate reader. The difference in absorbance is thus relative to the extent of cell survival. |
| In vitro | Losartan competes with the binding of angiotensin II to AT1 receptors, with an IC50 of 20 nM[1]. At 40 μM, losartan affects ISC and prevents the effect of ANGII on ISC[2]. It significantly reduces Ang II-mediated cell proliferation in endometrial cancer cells, with a greater antiproliferative effect when combined with anti-miR-155 compared to each drug alone[3]. |
| In vivo | Losartan (0.6 g/L, p.o.)-treated Fbn1C1039 g/+ mice show reduced distal airspace caliber compared to placebo-treated counterparts. The dosages of losartan and propranolol are titrated to achieve similar hemodynamic effects. Analysis of pSmad2 nuclear staining indicates that losartan antagonizes TGF-β signaling in the aortic wall of Fbn1C1039 g/+ mice, improving lung disease manifestations independently of hemodynamics[4]. Losartan (10 mg/kg, intraarterial injection) increases blood angiotensin levels by four- to sixfold. Losartan (10 mg/kg, i.p.) increases plasma renin levels by 100-fold, decreases plasma angiotensinogen levels to 24% of control, and leaves plasma aldosterone levels unchanged[5]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 45 mg/mL (106.41 mM)
|
| Keywords | DuP 753 | Angiotensin Receptor | DuP753 | Losartan | inhibit | Inhibitor |
| Inhibitors Related | Olmesartan Medoxomil | Tranilast | Enalapril Maleate | Azilsartan Methyl Ester | Sacubitril/Valsartan | Azilsartan | Irbesartan | Ramipril | Captopril | Valsartan Methyl Ester |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | NO PAINS Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
United States
